Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival

Cancer Research

Volumn 66, Issue 6, 2006, Pages 3323-3330

  Li, Donghui ^a   Liu, Hui ^a   Jiao, Li ^a   Chang, David Z ^a   Beinart, Garth ^a   Wolff, Robert A ^a   Evans, Douglas B ^a   Hassan, Manal M ^a   Abbruzzese, James L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; FLUOROURACIL; GEMCITABINE; RAD51 PROTEIN; RAD54 PROTEIN; RECA PROTEIN; RECQ HELICASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DNA REPAIR; DNA STRAND BREAKAGE; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; RAD54L GENE; RADIOSENSITIZATION; RECQ1 GENE; TREATMENT OUTCOME; XRCC2 GENE; XRCC3 GENE;

ADENOSINE TRIPHOSPHATASES; ADULT; AGED; AGED, 80 AND OVER; ALLELES; CARCINOMA, PANCREATIC DUCTAL; DNA HELICASES; DNA REPAIR; DNA-BINDING PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECOMBINATION, GENETIC; RECQ HELICASES; SURVIVAL RATE;

EID: 33645514237     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3032     Document Type: Article

References (40)

1. Bosken CH, Wei Q, Amos CI, et al. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 2002;94:1091-9.
2. Camps C, Sarries C, Roig B, et al. Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin- treated advanced non-small-cell lung cancer patients. Clin Lung Cancer 2003;4:237-41.
3. Park DJ, Stoehlmacher J, Zhang W, et al. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001;61:8654-8.
4. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004;22:2594-601.
5. Rosell R, Taron M, Alberola V, et al. Genetic testing for chemotherapy in non-small cell lung cancer. Lung Cancer 2003;41 Suppl 1:S97-102.
6. Oettle H, Arnold D, Hempel C, et al. The role of gemcitabine alone and in combination in the treatment of pancreatic cancer. Anticancer Drugs 2000;11:771-86.
7. Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensitization. Semin Oncol 1997;24:S7-24-S7-8.
8. Gregoire V, Beauduin M, Bruniaux M, et al. Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresis. Int J Radiat Biol 1998;73:511-20.
9. Lawrence TS, Blackstock AW, McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 2003;13:13-21.
10. Crul M, van Waardenburg RC, Bocxe S, et al. DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem Pharmacol 2003;65:275-82.
11. Wachters FM, van Putten JW, Maring JG, et al. Selective targeting of homologous DNA recombination repair by gemcitabine. Int J Radiat Oncol Biol Phys 2003;57:553-62.
12. Peltenburg LT. Radiosensitivity of tumor cells. Oncogenes and apoptosis. Q J Nucl Med 2000;44:355-64.
13. Shenouda G. Strand-break repair and radiation resistance, DNA repair in cancer therapy. Totowa: Humana Press; 2004. p. 257-72.
14. Peterson CL, Cote J. Cellular machineries for chromosomal DNA repair. Genes Dev 2004;18:602-16.
15. Kaneko H, Fukao T, Kondo N. The function of RecQ helicase gene family (especially BLM) in DNA recombination and joining. Adv Biophys 2004;38:45-64.
16. Mohaghegh P, Hickson ID. DNA helicase deficiencies associated with cancer predisposition and premature ageing disorders. Hum Mol Genet 2001;10:741-6.
17. Khakhar RR, Cobb JA, Bjergbaek L, et al. RecQ helicases: multiple roles in genome maintenance. Trends Cell Biol 2003;13:493-501.
18. Hickson ID. RecQ helicases: caretakers of the genome. Nat Rev Cancer 2003;3:169-78.
19. Cui S, Klima R, Ochem A, et al. Characterization of the DNA-unwinding activity of human RECQ1, a helicase specifically stimulated by human replication protein A. J Biol Chem 2003;278:1424-32.
20. Sharma S, Sommers JA, Choudhary S, et al. Biochemical analysis of the DNA unwinding and strand annealing activities catalyzed by human RECQ1. J Biol Chem 2005;280:28072-84.
21. Doherty KM, Sharma S, Uzdilla LA, et al. RECQ1 helicase interacts with human mismatch repair factors that regulate genetic recombination. J Biol Chem 2005;280:28085-94.
22. Kanaar R, Troelstra C, Swagemakers SM, et al. Human and mouse homologs of the Saccharomyces cerevisiae RAD54 DNA repair gene: evidence for functional conservation. Curr Biol 1996;6:828-38.
23. Pluth JM, Fried LM, Kirchgessner CU. Severe combined immunodeficient cells expressing mutant hRAD54 exhibit a marked DNA double-strand break repair and error-prone chromosome repair defect. Cancer Res 2001;61:2649-55.
24. Ristic D, Wyman C, Paulusma C, et al. The architecture of the human Rad54-DNA complex provides evidence for protein translocation along DNA, Proc Natl Acad Sci U S A 2001;98:8454-60.
25. Leone PE, Mendiola M, Alonso J, et al. Implications of a RAD54L polymorphism (2290C/T) in human meningiomas as a risk factor and/or a genetic marker. BMC Cancer 2003;3:6.
26. Mohindra A, Bolderson E, Stone J, et al. A tumour-derived mutant allele of XRCC2 preferentially suppresses homologous recombination at DNA replication forks. Hum Mol Genet 2004;13:203-12.
27. Pierce AJ, Johnson RD, Thompson LH, et al. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 1999;13:2633-8.
28. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001;27:247-54.
29. Deans B, Griffin CS, O'Regan P, et al. Homologous recombination deficiency leads to profound genetic instability in cells derived from Xrcc2-knockout mice. Cancer Res 2003;63:8181-7.
30. Forget AL, Bennett BT, Knight KL. Xrcc3 is recruited to DNA double strand breaks early and independent of Rad51. J Cell Biochem 2004;93:429-36.
31. Price EA, Bourne SL, Radbourne R, et al. Rare microsatellite polymorphisms in the DNA repair genes XRCC1, XRCC3 and XRCC5 associated with cancer in patients of varying radiosensitivity. Somat Cell Mol Genet 1997;23:237-47.
32. Rafii S, O'Regan P, Xinarianos G, et al. A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer. Hum Mol Genet 2002;11:1433-8.
33. Araujo FD, Pierce AJ, Stark JM, et al. Variant XRCC3 implicated in cancer is functional in homology-directed repair of double-strand breaks. Oncogene 2002;21:4176-80.
34. Wang W, Seki M, Narita Y, et al. Functional relation among RecQ family helicases RecQL1, RecQL5, and BLM in cell growth and sister chromatid exchange formation. Mol Cell Biol 2003;23:3527-35.
35. Essers J, Hendriks RW, Swagemakers SM, et al. Disruption of mouse RAD54 reduces ionizing radiation resistance and homologous recombination. Cell 1997;89:195-204.
36. Dronkert ML, Beverloo HB, Johnson RD, et al. Mouse RAD54 affects DNA double-strand break repair and sister chromatid exchange. Mol Cell Biol 2000;20:3147-56.
37. Rasio D, Murakumo Y, Robbins D, et al. Characterization of the human homologue of RAD54: a gene located on chromosome 1p32 at a region of high loss of heterozygosity in breast tumors. Cancer Res 1997;57:2378-83.
38. Matsuda M, Miyagawa K, Takahashi M, et al. Mutations in the RAD54 recombination gene in primary cancers. Oncogene 1999;18:3427-30.
39. Liu N, Lamerdin RS, Tebbs RS, et al. XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA crosslinks and other damages. Mol Cell 1998;1:783-93.
40. Phillips KA, Van Bebber SL. Measuring the value of pharmacogenomics. Nat Rev Drug Discov 2005;4:500-9.